CN101827523A - 用于治疗眼部疾病或病症的制剂 - Google Patents

用于治疗眼部疾病或病症的制剂 Download PDF

Info

Publication number
CN101827523A
CN101827523A CN200880112404A CN200880112404A CN101827523A CN 101827523 A CN101827523 A CN 101827523A CN 200880112404 A CN200880112404 A CN 200880112404A CN 200880112404 A CN200880112404 A CN 200880112404A CN 101827523 A CN101827523 A CN 101827523A
Authority
CN
China
Prior art keywords
rapamycin
variations
liquid formulation
therapeutic agent
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880112404A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·多
S·穆登巴
T·尼瓦焦利
D·A·韦伯
S·法鲁克
S·K·塔哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
MacuSight Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MacuSight Inc filed Critical MacuSight Inc
Publication of CN101827523A publication Critical patent/CN101827523A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880112404A 2007-08-16 2008-08-18 用于治疗眼部疾病或病症的制剂 Pending CN101827523A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96528207P 2007-08-16 2007-08-16
US96525807P 2007-08-16 2007-08-16
US60/965,258 2007-08-16
US60/965,282 2007-08-16
PCT/US2008/073520 WO2009023877A2 (en) 2007-08-16 2008-08-18 Formulations for treatment of ocular diseases or conditions

Publications (1)

Publication Number Publication Date
CN101827523A true CN101827523A (zh) 2010-09-08

Family

ID=40351498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880112404A Pending CN101827523A (zh) 2007-08-16 2008-08-18 用于治疗眼部疾病或病症的制剂

Country Status (6)

Country Link
EP (1) EP2187743B1 (enExample)
JP (1) JP2010536797A (enExample)
KR (1) KR20100055482A (enExample)
CN (1) CN101827523A (enExample)
ES (1) ES2507078T3 (enExample)
WO (1) WO2009023877A2 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103239399A (zh) * 2013-05-30 2013-08-14 苏州普罗达生物科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
CN107080843A (zh) * 2011-10-13 2017-08-22 爱尔皮奥治疗有限公司 眼病的治疗
CN108025000A (zh) * 2015-09-18 2018-05-11 参天制药株式会社 角膜真菌病的预防或治疗剂
CN109152769A (zh) * 2016-05-25 2019-01-04 参天制药株式会社 西罗莫司用于治疗伴有持续性水肿的渗出性年龄相关性黄斑变性的用途
CN109431997A (zh) * 2018-12-20 2019-03-08 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
CN110337296A (zh) * 2016-12-27 2019-10-15 犹他大学研究基金会 眼内药物递送装置和相关方法
CN111511352A (zh) * 2017-12-22 2020-08-07 科斯莫科技有限公司 液体递送组合物
CN112263670A (zh) * 2020-10-22 2021-01-26 温州医科大学 硼替佐米及其制剂在制备治疗脉络膜新生血管性相关疾病药物上的应用及滴眼液制备方法
CN115192517A (zh) * 2015-02-02 2022-10-18 参天制药股份有限公司 多泡沫体及其眼睑施用
CN115813863A (zh) * 2022-12-15 2023-03-21 广州因明生物医药科技股份有限公司 一种可自发团聚的微球及其制备方法
WO2025007888A1 (zh) * 2023-07-05 2025-01-09 沈阳兴齐眼药股份有限公司 眼用药物组合物、其制备方法、含其的眼用药盒及应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2564842A1 (en) 2005-06-01 2013-03-06 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2777479C (en) 2009-04-28 2017-10-17 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
KR101674457B1 (ko) * 2013-11-04 2016-11-09 아주대학교산학협력단 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
ES2969514T3 (es) * 2015-03-18 2024-05-21 Santen Pharmaceutical Co Ltd Composición farmacéutica de liberación sostenida
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
US20190015513A1 (en) * 2015-08-28 2019-01-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
BR112018077259A2 (pt) * 2016-06-30 2019-06-18 Durect Corporation formulações depot
IL267869B2 (en) * 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
JP2021530463A (ja) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
CN114845714B (zh) * 2019-12-26 2024-05-14 参天制药株式会社 含有西罗莫司或其盐的水性混悬组合物
WO2022266127A1 (en) * 2021-06-15 2022-12-22 Onl Therapeutics, Inc. Methods and compositions for treating ocular disorders and diseases
CN115337263B (zh) * 2022-08-09 2023-10-03 江苏汉晨药业有限公司 一种盐酸洛美沙星滴眼液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
AU2003272471B2 (en) * 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
BRPI0607606B1 (pt) * 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107080843A (zh) * 2011-10-13 2017-08-22 爱尔皮奥治疗有限公司 眼病的治疗
CN103239399A (zh) * 2013-05-30 2013-08-14 苏州普罗达生物科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
CN103239399B (zh) * 2013-05-30 2016-06-29 山东兴瑞生物科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
CN115192517A (zh) * 2015-02-02 2022-10-18 参天制药股份有限公司 多泡沫体及其眼睑施用
CN108025000A (zh) * 2015-09-18 2018-05-11 参天制药株式会社 角膜真菌病的预防或治疗剂
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
CN109152769A (zh) * 2016-05-25 2019-01-04 参天制药株式会社 西罗莫司用于治疗伴有持续性水肿的渗出性年龄相关性黄斑变性的用途
CN110337296A (zh) * 2016-12-27 2019-10-15 犹他大学研究基金会 眼内药物递送装置和相关方法
CN111511352A (zh) * 2017-12-22 2020-08-07 科斯莫科技有限公司 液体递送组合物
US12011483B2 (en) 2017-12-22 2024-06-18 Cosmo Technologies Ltd. Liquid delivery composition
CN109431997A (zh) * 2018-12-20 2019-03-08 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
CN112263670A (zh) * 2020-10-22 2021-01-26 温州医科大学 硼替佐米及其制剂在制备治疗脉络膜新生血管性相关疾病药物上的应用及滴眼液制备方法
CN115813863A (zh) * 2022-12-15 2023-03-21 广州因明生物医药科技股份有限公司 一种可自发团聚的微球及其制备方法
WO2025007888A1 (zh) * 2023-07-05 2025-01-09 沈阳兴齐眼药股份有限公司 眼用药物组合物、其制备方法、含其的眼用药盒及应用

Also Published As

Publication number Publication date
ES2507078T3 (es) 2014-10-14
EP2187743B1 (en) 2014-07-30
WO2009023877A3 (en) 2009-04-09
WO2009023877A2 (en) 2009-02-19
EP2187743A2 (en) 2010-05-26
EP2187743A4 (en) 2010-10-27
JP2010536797A (ja) 2010-12-02
KR20100055482A (ko) 2010-05-26

Similar Documents

Publication Publication Date Title
US8663639B2 (en) Formulations for treating ocular diseases and conditions
US9381153B2 (en) Liquid formulations for treatment of diseases or conditions
EP2187743B1 (en) Rapamycin formulations for treatment of age related macular degeneration
US20170049786A1 (en) Mtor pathway inhibitors for treating ocular disorders
CN101137370B (zh) 用于治疗疾病或病症的液体制剂
US20060257450A1 (en) Drug delivery systems for treatment of diseases or conditions
AU2012200274B2 (en) Liquid formulations for treatment of diseases or conditions
HK1200365B (zh) 用於治疗疾病或病症的液体制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SANTEN PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: MACUSIGHT INC.

Effective date: 20111025

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20111025

Address after: Osaka Japan

Applicant after: Santen Pharmaceutical Co., Ltd.

Address before: American California

Applicant before: Macusight Inc.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100908